YPEL2

Summary

YPEL2 (yippee like 2, HGNC:18326) is a protein-coding gene on chromosome 17q22, encoding Protein yippee-like 2 (Q96QA6).

Predicted to enable metal ion binding activity. Predicted to be located in nucleolus.

Source: NCBI Gene 388403 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Limited, GenCC)
• GWAS associations: 26
• Clinical variants (ClinVar): 9 total
• MANE Select transcript: NM_001005404

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18326
Approved symbol	YPEL2
Name	yippee like 2
Location	17q22
Locus type	gene with protein product
Status	Approved
Aliases	FKSG4
Ensembl gene	ENSG00000175155
Ensembl biotype	protein_coding
OMIM	609723
Entrez	388403

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000312655, ENST00000581865, ENST00000582192, ENST00000582813, ENST00000585166, ENST00000672916

RefSeq mRNA: 1 — MANE Select: NM_001005404 NM_001005404

CCDS: CCDS32695

Canonical transcript exons

ENST00000312655 — 5 exons

Exon	Start	End
ENSE00001207678	59397101	59401729
ENSE00001324083	59353215	59353526
ENSE00002691772	59331655	59331824
ENSE00003541414	59388327	59388370
ENSE00003687887	59389360	59389468

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 99.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.9234 / max 196.1027, expressed in 1679 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161954	10.4755	1646
161955	3.2728	845
161953	1.1751	548

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.26	gold quality
endothelial cell	CL:0000115	97.59	gold quality
oviduct epithelium	UBERON:0004804	97.22	gold quality
tibialis anterior	UBERON:0001385	96.34	gold quality
inferior vagus X ganglion	UBERON:0005363	95.52	gold quality
amniotic fluid	UBERON:0000173	95.51	gold quality
saphenous vein	UBERON:0007318	95.46	gold quality
corpus callosum	UBERON:0002336	95.15	gold quality
deltoid	UBERON:0001476	94.81	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.79	gold quality
vena cava	UBERON:0004087	94.73	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.50	gold quality
subthalamic nucleus	UBERON:0001906	94.43	gold quality
Brodmann (1909) area 46	UBERON:0006483	94.36	gold quality
left ventricle myocardium	UBERON:0006566	94.05	gold quality
medulla oblongata	UBERON:0001896	93.83	gold quality
calcaneal tendon	UBERON:0003701	93.66	gold quality
substantia nigra pars reticulata	UBERON:0001966	93.59	gold quality
substantia nigra pars compacta	UBERON:0001965	93.56	gold quality
ileal mucosa	UBERON:0000331	93.50	gold quality
dorsal plus ventral thalamus	UBERON:0001897	93.50	gold quality
superior vestibular nucleus	UBERON:0007227	93.43	gold quality
germinal epithelium of ovary	UBERON:0001304	93.34	gold quality
vastus lateralis	UBERON:0001379	93.23	gold quality
trigeminal ganglion	UBERON:0001675	93.20	gold quality
buccal mucosa cell	CL:0002336	93.11	gold quality
oocyte	CL:0000023	92.92	gold quality
layer of synovial tissue	UBERON:0007616	92.88	gold quality
ventral tegmental area	UBERON:0002691	92.77	gold quality
dorsal root ganglion	UBERON:0000044	92.72	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-10018	yes	171.44
E-MTAB-7316	yes	31.11
E-GEOD-137537	yes	31.05
E-ANND-3	yes	15.82

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

274 targeting YPEL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1193	100.00	65.93	529
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913

Literature-anchored findings (GeneRIF, showing 2)

• Structural Variants Create New Topological-Associated Domains and Ectopic Retinal Enhancer-Gene Contact in Dominant Retinitis Pigmentosa. (PMID:33022222)
• A novel role for YPEL2 in mediating endothelial cellular senescence via the p53/p21 pathway. (PMID:36963468)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ypel2b	ENSDARG00000087258
mus_musculus	Ypel2	ENSMUSG00000018427
rattus_norvegicus	Ypel2	ENSRNOG00000005447
drosophila_melanogaster	Ypel	FBGN0030183

Paralogs (10): L2HGDH (ENSG00000087299), YPEL3 (ENSG00000090238), PDPR (ENSG00000090857), YPEL1 (ENSG00000100027), FOXRED1 (ENSG00000110074), YPEL5 (ENSG00000119801), SARDH (ENSG00000123453), DMGDH (ENSG00000132837), AMT (ENSG00000145020), YPEL4 (ENSG00000166793)

Protein

Protein identifiers

Protein yippee-like 2 — Q96QA6 (reviewed: Q96QA6)

All UniProt accessions (2): A0A5F9ZH55, Q96QA6

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. May interact with FAM168B.

Subcellular location. Nucleus. Nucleolus.

Tissue specificity. Widely expressed. Detected in fetal and adult kidney, heart, liver, lung and skeletal muscle.

Similarity. Belongs to the yippee family.

RefSeq proteins (1): NP_001005404* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004910	Yippee/Mis18/Cereblon	Domain
IPR034751	Yippee	Domain
IPR039058	Yippee_fam	Family

Pfam: PF03226

UniProt features (6 total): binding site 4, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96QA6-F1	91.14	0.81

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 23; 26; 79; 82

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 226 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, ATACCTC_MIR202, GOZGIT_ESR1_TARGETS_DN, ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, ACATTCC_MIR1_MIR206, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, YAMAZAKI_TCEB3_TARGETS_UP, CTTTGTA_MIR524, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, chr17q22, AACATTC_MIR4093P, GOCC_NUCLEOLUS, GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D, DODD_NASOPHARYNGEAL_CARCINOMA_DN

GO Biological Process (0):

GO Molecular Function (2): metal ion binding (GO:0046872), protein binding (GO:0005515)

GO Cellular Component (2): nucleolus (GO:0005730), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cation binding	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

524 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
YPEL2	DHX40	Q8IX18	629
YPEL2	CHCT1	Q86WR6	409
YPEL2	TUBD1	Q9UJT1	397
YPEL2	ZBTB44	Q8NCP5	380
YPEL2	RNFT1	Q5M7Z0	374
YPEL2	KLHL24	Q6TFL4	372
YPEL2	USP32	Q8NFA0	369
YPEL2	APPBP2	Q92624	361
YPEL2	MOSMO	Q8NHV5	359
YPEL2	ZNF846	Q147U1	358
YPEL2	C1orf226	A1L170	356
YPEL2	NBEAL1	Q6ZS30	352
YPEL2	PLCXD2	Q0VAA5	349
YPEL2	TEX14	Q8IWB6	348
YPEL2	PTRH2	Q9Y3E5	348

IntAct

10 interactions, top by confidence:

A	B	Type	Score
SH2D4A	YPEL2	psi-mi:“MI:0915”(physical association)	0.560
PICK1	YPEL2	psi-mi:“MI:0915”(physical association)	0.560
YPEL2	SH2D4A	psi-mi:“MI:0915”(physical association)	0.560
SRPK2	YPEL2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
YPEL2	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
YPEL2	Fam168b	psi-mi:“MI:0915”(physical association)	0.370
YPEL2	PICK1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): YPEL2 (Affinity Capture-RNA), YPEL2 (Two-hybrid), YPEL2 (Two-hybrid), YPEL2 (Affinity Capture-RNA), YPEL2 (Biochemical Activity), YPEL2 (Biochemical Activity)

ESM2 similar proteins: A2VE01, A6QPH8, D3ZRP6, O60688, P00860, P11926, P27117, P27118, P27119, P27120, P48455, P61236, P61237, Q16HW7, Q1RMS5, Q24208, Q2YDI3, Q3SYW1, Q5EBF1, Q5PQL4, Q5RDN9, Q5VST6, Q5XID5, Q5ZIZ4, Q5ZJ01, Q65Z54, Q65Z56, Q65Z57, Q65Z58, Q65Z59, Q65Z93, Q65Z95, Q6AY17, Q6DCC5, Q6DEY3, Q6DKB0, Q6NWI4, Q7M759, Q8L5V0, Q96NS1

Diamond homologs: A6QPH8, O44440, O60688, P38191, P59234, P61236, P61237, P62699, P62700, Q2V3E2, Q2YDI3, Q3ZBE7, Q4R4Q6, Q5RDN9, Q5RDU7, Q5XID5, Q65Z54, Q65Z55, Q65Z56, Q65Z57, Q65Z58, Q65Z59, Q65Z93, Q65Z95, Q6NWI4, Q8S5M8, Q96NS1, Q96QA6, Q9C777, Q9DG42, Q9ESC7, Q9FN32, Q9LY56, Q9SR97, Q9T096, Q9U3G6, Q9URW3, Q9W2X7, Q9XZF0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

9 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1239 predictions. Top by Δscore:

Variant	Effect	Δscore
17:59331820:GCCGG:G	donor_gain	1.0000
17:59331822:CGGG:C	donor_loss	1.0000
17:59331823:GG:G	donor_gain	1.0000
17:59331823:GGGTA:G	donor_loss	1.0000
17:59331824:GG:G	donor_gain	1.0000
17:59331824:GGT:G	donor_loss	1.0000
17:59331825:G:GG	donor_gain	1.0000
17:59331825:GTA:G	donor_loss	1.0000
17:59331826:T:G	donor_loss	1.0000
17:59388321:T:G	acceptor_gain	1.0000
17:59388325:A:AG	acceptor_gain	1.0000
17:59388326:G:GA	acceptor_gain	1.0000
17:59388326:GTC:G	acceptor_gain	1.0000
17:59388369:GT:G	donor_gain	1.0000
17:59388371:G:GG	donor_gain	1.0000
17:59389345:T:A	acceptor_gain	1.0000
17:59389345:T:TA	acceptor_loss	1.0000
17:59389347:T:TA	acceptor_gain	1.0000
17:59389352:C:A	acceptor_gain	1.0000
17:59389356:ATAG:A	acceptor_loss	1.0000
17:59389357:T:G	acceptor_gain	1.0000
17:59389358:A:AG	acceptor_gain	1.0000
17:59389359:G:GA	acceptor_gain	1.0000
17:59389359:GA:G	acceptor_gain	1.0000
17:59389359:GAGT:G	acceptor_gain	1.0000
17:59389359:GAGTT:G	acceptor_gain	1.0000
17:59389464:AATAC:A	donor_gain	1.0000
17:59389465:ATAC:A	donor_gain	1.0000
17:59389465:ATACG:A	donor_loss	1.0000
17:59389466:TAC:T	donor_gain	1.0000

AlphaMissense

778 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:59353476:T:C	C23R	1.000
17:59353477:G:A	C23Y	1.000
17:59353478:C:G	C23W	1.000
17:59353485:T:C	C26R	1.000
17:59353486:G:A	C26Y	1.000
17:59353487:C:G	C26W	1.000
17:59353516:T:C	L36P	1.000
17:59353521:T:C	S38P	1.000
17:59353522:C:T	S38F	1.000
17:59388330:T:A	F41I	1.000
17:59388330:T:C	F41L	1.000
17:59388330:T:G	F41V	1.000
17:59388331:T:C	F41S	1.000
17:59388331:T:G	F41C	1.000
17:59388332:C:A	F41L	1.000
17:59388332:C:G	F41L	1.000
17:59388336:G:A	G43R	1.000
17:59388336:G:C	G43R	1.000
17:59388337:G:A	G43E	1.000
17:59388345:G:A	G46R	1.000
17:59388345:G:C	G46R	1.000
17:59388346:G:A	G46E	1.000
17:59388346:G:T	G46V	1.000
17:59388352:C:A	A48E	1.000
17:59388358:T:A	L50H	1.000
17:59388358:T:C	L50P	1.000
17:59389366:T:A	N56K	1.000
17:59389366:T:G	N56K	1.000
17:59389392:G:C	R65P	1.000
17:59389398:T:C	L67S	1.000

dbSNP variants (sampled 300 via entrez): RS1000037500 (17:59332237 C>T), RS1000040539 (17:59377983 A>G), RS1000054745 (17:59391940 G>A), RS1000070867 (17:59400726 G>A), RS1000084767 (17:59376449 C>A,G), RS1000164509 (17:59329821 A>G), RS1000166679 (17:59382988 T>C), RS1000190729 (17:59332172 G>A), RS1000193370 (17:59368583 A>G), RS1000200093 (17:59337403 A>T), RS1000219339 (17:59368149 T>C), RS1000283288 (17:59367743 A>T), RS1000341844 (17:59395676 T>C), RS1000345463 (17:59334962 G>T), RS1000349839 (17:59386086 G>A)

Disease associations

OMIM: gene MIM:609723 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Limited	Autosomal dominant

Mondo (1): retinitis pigmentosa (MONDO:0019200)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST002500_45	QT interval	8.000000e-06
GCST008514_27	Peginterferon alfa-2a treatment response in chronic hepatitis B infection	5.000000e-06
GCST010002_126	Refractive error	7.000000e-42
GCST010796_3501	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-10
GCST010796_3502	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_3503	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-09
GCST010796_3504	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_3505	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_4709	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-11
GCST010796_4710	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_4711	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_4712	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_4713	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-09
GCST010796_4714	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-10
GCST010796_4715	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-10
GCST010796_4716	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-11
GCST010796_4717	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-11
GCST010796_4718	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-10
GCST010796_4719	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-10
GCST010796_4720	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-10
GCST010796_4721	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-10
GCST010796_4722	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_4723	Electrocardiogram morphology (amplitude at temporal datapoints)	9.000000e-09
GCST010796_4724	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-09
GCST010796_4725	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-11
GCST011010_16	Electrocardiographic traits (multivariate)	5.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0010103	response to peginterferon alfa-2a
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

62 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation, increases expression	8
trichostatin A	affects cotreatment, decreases expression, affects expression	4
entinostat	decreases expression, affects cotreatment	2
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	2
Vorinostat	affects cotreatment, decreases expression	2
Air Pollutants	increases abundance, decreases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Estradiol	decreases expression, affects expression	2
Smoke	increases abundance, decreases expression, decreases reaction	2
GSK-J4	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	increases expression	1
sodium arsenate	increases abundance, decreases expression	1
2-butenal	increases expression	1
arsenite	affects binding, decreases reaction	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
didecyldimethylammonium	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression	1
phenethyl isothiocyanate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
clothianidin	increases expression	1
nutlin 3	increases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

234 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
NCT01068561	PHASE1	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa